Futura Medical plc (“Futura” or the “Company”) is an AIM listed pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain.
In 2021, Futura received EU regulatory approval for its breakthrough, fast acting topical gel formulation for the treatment of erectile dysfunction (“ED”) and is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction known as MED3000 (Eroxon™). In addition, the remaining clinical study that the Company believes is required in order to submit MED3000 for US regulatory approval as a DeNovo medical device for ED treatment, with OTC classification commenced patient recruitment.
The Board sought to appoint an additional independent main board director and Chair of the Remuneration Committee to represent shareholder interests, the profile sought was of an ideally US based independent Non-Executive Director who would bring an extensive strategic commercial track-record in the US and International OTC market.
Futura Medical’s Board mandated PIR International to undertake this important appointment, alongside the search for a UK based finance Non-Executive Director and Chair of the Audit Committee. Following an expedited search, two high calibre profiles, Jeff Needham and Andrew Unitt, were promptly appointed to the board.
James Barder, Chief Executive Officer of Futura, commented: “We have previously used PIR International for the successful recruitment of senior pharmaceutical staff and therefore had no hesitation in mandating them once more in the search for two non-executive directors to join the board of Futura. I was impressed once more by their professionalism and delighted with the outcome.”
James Barder, Chief Executive Officer, Futura Medical PLC